
CLAIMS

1. A compound of formula I:




I

wherein:

R is selected from H and (C_1-C_{20})hydrocarbyl.

2. A compound according to claim 1 of formula II:



II.

3. A compound according to claim 2 wherein R is selected from H and aliphatic (C_1-C_{20})hydrocarbyl optionally substituted with one or two phenyl groups with the proviso that R contains twenty carbons or less.

4. A compound according to claim 2 wherein R is H or C_nH_m, and wherein:

n is 1 and m is 3;

n is 2 and m is 5;

n is 3 and m is 3, 5, or 7;

n is 4 and m is 5, 7, or 9;

n is 5 and m is 7, 9, or 11;

n is 6 and m is 5, 7, 9, 11, or 13.

n is 7 and m is 7, 9, 11, 13, or 15;

n is 8 and m is 5, 7, 9, 11, 13, 15, or 17;

n is 9 and m is 7, 9, 11, 13, 15, 17, or 19;

n is 10 and m is 7, 9, 11, 13, 15, 17, 19, or 21;

n is 11 and m is 9, 11, 13, 15, 17, 19, 21, or 23;

n is 12 and m is 7, 9, 11, 13, 15, 17, 19, 21, 23, or 25;

n is 13 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, or 27;

n is 14 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, or 29;

n is 15 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31;


n is 16 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 33;






n is 17 and m is 11, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35;

n is 18 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, or 37;

n is 19 and m is 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39; or




n is 20 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, or 41.




5. A compound according to claim 3 wherein R is chosen from: H, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, 1-methylpropyl, 1-methyl-2-ethylbutyl, 2-ethylbutyl, 2-methylpropyl, tert-butyl, 2-methylcyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopropylmethyl (i.e., ), n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl,




cyclobutylmethyl (i.e., ), 2-(cyclopropyl)ethyl (i.e., ), cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 3-(cyclopropyl)propyl (i.e., ), 2-(cyclobutyl)ethyl (i.e., ), cyclopentylmethyl (i.e., ), cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, dicyclohexylmethyl, n-octyl, benzyl, diphenylmethyl, decyl, dodecyl, tetradecyl, hexadecyl, hexadec-9-enyl, octadecyl, octadec-9-enyl, octadec-9,12-dienyl, 2-propylpentyl, 2-butylhexyl, 2-pentylheptyl, 2-hexyloctyl.



6. A compound according to claim 5 wherein R is chosen from: H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, 2-methylbutyl, and 2-ethylbutyl.









7. A compound according to claim 2, with a structure selected from:

, , ,







, , ,

, , ,


, ,


,

,

,

,

,

,

, and

.


8. A compound according to claim 7, with a structure selected from:


,

,

,

,

, and

.


9. A compound according to claim 8, with a structure selected from




10. A compound according to claim 8, with a structure selected from



11. A compound according to claim 8, with a structure selected from



12. A compound according to claim 8, with a structure selected from



13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

14. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a seizure disorder~~A method of treating a seizure disorder, comprising administering to a subject a therapeutically or prophylactically effective amount of the compound of claim 1~~.

15. The use ~~method~~ according to claim 14, wherein the seizure disorder is epilepsy.

16. The use ~~method~~ according to claim 14, wherein the seizure disorder is status epilepticus.

17. The use ~~method~~ according to claim 14, wherein the seizure disorder comprises partial-onset seizures or primary generalized tonic-clonic seizures, or any combination thereof.

18. The use ~~method~~ according to claim 14, wherein the seizure disorder results from a heritable genetic seizure disorder.

19. The use ~~method~~ according to claim 14, wherein the seizure disorder results from a brain tumor, a concussive brain injury, or a penetrating brain injury.

20. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pain~~A method of treating pain, comprising administering to a subject a therapeutically or prophylactically effective amount of the compound of claim 1~~.